Industry Verticals »

All Categories

Insights »

About TMR »

Thrombosis Drugs Market

Schedule a Call

Thrombosis Drugs Market

Thrombosis Drugs Market (Drug Class - Factor Xa Inhibitor, Low Molecular Weight Heparin, P2Y12 Platelet Inhibitor; Indication - Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Global Thrombosis Drugs Market – An Overview

Over the forecast period of 2018 to 2026, notable growth would be charted by global thrombosis drugs market, creating a string of advantageous opportunities and driving the market valuation to a higher worth. Multiple factors of growth are helping the global thrombosis drugs market stay on an upward and steep growth curve over the stated period. Some of these include poor lifestyle choices gaining foothold among consumers, increasing burden of cardiovascular diseases, and growing government efforts towards improvement in healthcare outcomes.

A detailed overview of trends and drivers that are contributing significantly to growth in the global thrombosis drugs market can be found below:

  •  Number of people in the geriatric age group is increasing and it is increasing at a rapid pace. As per research undertaken recently, there would be an increase from approximately 970million in 2017 to 2 billion in 2050 in the number of people aged 60 and above. This phenomenon is going to be quite pronounced in regions of Europe and North America where one in every four people will be aged 65 and above by this year. One in every six people will be the ratio of people in this age group across the world. This demographic is a major consumer of thrombosis drugs and is therefore set to propel notable growth in the market.
  • Research and development in the market is witnessing increase in activity and intensity – a result of growing number of cases of cardiovascular diseases. Poor diet and habits such as excessive drinking and smoking is leading to increase in incidence of these diseases across the globe. This is contributing massively to growth that is anticipated in the global thrombosis drugs market. Additionally, obesity or being over-weight is also increasing the risk of CVD, driving demand for thrombosis drugs by a notable factor over the forecast period,

Global Thrombosis Drugs Market - Snapshot

Thrombosis is the medical term for an abnormal blood clot in an artery or vein. Thrombosis drugs are used to prevent or treat the blood clot, which can cause different thrombotic events. Medication to treat is likely to include anticoagulants drugs and thrombin inhibitors drugs. In terms of revenue, the global thrombosis market was valued at approximately US$ 20,000 Mn in 2017 and is anticipated to surpass US$ 47,000 Mn by 2026, expanding at a CAGR of 9.5% from 2018 to 2026. Rise in the number of patients affected by thrombosis and availability of new drugs formulation products with improved features are likely to fuel the global thrombosis drugs market from 2018 to 2026.

Thrombosis drugs are generally blood thinners. These drugs decrease the clotting power of blood and consequently, the chances of thrombosis events, such as pulmonary embolism, decrease. These drugs are available in the form of injection, capsule, and tablet. Key players are focusing on the development of drugs with better efficacy. For instance, Grifols Therapeutics Inc., a U.S.-based biotechnology company is projected to launch AT- lll, a new type of human recombinant thrombosis drugs for the indication of cardiac surgery cardiopulmonary bypass. Such key developments are likely to fuel the global thrombosis drugs market in the near future. However, the high price of non-vitamin K oral anticoagulant drugs and the availability of generic drugs are likely to hamper the global thrombosis drugs market during the forecast period.

thrombosis-drugs-market.jpg

Several unmet needs are anticipated to create significant opportunities for existing players and new entrants in the global thrombosis drugs market. Rapid technological advancements in treatment therapies create opportunities for players operating in the global thrombosis drugs market. Ongoing developments in thrombosis drugs, such as Revo Biologic’s ATryn with continuous infusion of drugs are likely drive the thrombosis drugs market during the forecast period.

The global thrombosis drugs market can be segmented based on drug class, indication, distribution channel, and geography. In terms of drug class, the factor Xa inhibitor segment dominated the market and is expected to continue this trend during the forecast period, followed by the P2Y12 platelet inhibitor segment. Increasing preference for the usage of oral anticoagulant drugs with predictable dose release response is likely to propel the segment during the forecast period. The low molecular weight heparin drug class segment, is likely to lose market share during the forecast period owing to patent expiry. Based on indication, the pulmonary embolism segment led the market, in terms of revenue, in 2017. The segment is projected to continue to dominate the market during the forecast period. In terms of distribution channel, the hospital pharmacies segment accounted for a large share of the market in 2017 and is likely to continue its dominance during the forecast period.

In terms of geography, North America held a major share of the global thrombosis drugs market in 2017. High utilization rate of new oral anticoagulant drugs is a key factor that propels the market in North America. Moreover, favorable reimbursement for the treatment of different thrombosis events under Medicare policy also boosts the market in this region. In terms of revenue, the market in Europe and Asia Pacific is projected to expand during the forecast period. Rising prevalence of deep vein thrombosis and increasing awareness about the treatment and usage of drugs to treat different thrombosis events in countries such as Brazil and South Africa are likely to boost the market in Latin America and Middle East & Africa.

Key companies operating in the global thrombosis drugs market, which are profiled in the report, include GlaxoSmithKline plc., Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and Pfizer, Inc. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base, and gain market share. For instance, in September 2014, Mylan Inc., acquired the U.S. commercialization, marketing, and intellectual property rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic of Arixtra from Aspen Global Incorporated. This acquisition enhanced Mylan Inc’s expansion opportunities in the U.S. market.

The global thrombosis drugs market has been segmented as follows:

Drug Class
  • Factor Xa Inhibitor
  • Low Molecular Weight Heparin
  • P2Y12 Platelet Inhibitor
  • Others

Indication
  • Pulmonary Embolism
  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Others

Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Geography
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

    Chapter 1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

    Chapter 2. Assumptions and Research Methodology

    Chapter 3. Executive Summary : Global Thrombosis Drugs Market

    Chapter 4. Market Overview
    4.1. Introduction
           4.1.1. Drug Class Overview
    4.2. Market Dynamics
           4.2.1. Drivers
           4.2.2. Restraints
           4.2.3. Opportunities
    4.3. Pipeline Analysis – Thrombosis Drugs Market
    4.4. Thrombosis Drugs Sales Analysis
    4.5. Thrombosis Drugs Market Value Chain Analysis
    4.6. Global Thrombosis Drugs Market Analysis and Forecasts, 2016–2026
           4.6.1. Market Revenue Projection (US$ Mn)
           4.6.2. Market Outlook
    4.7. Key Trends

    Chapter 5. Global Thrombosis Drugs Market Analysis and Forecasts, by Drug Class
    5.1. Key Findings / Developments
    5.2. Introduction & Definition
    5.3. Market Value Forecast, by Drug Class, 2017–2026
           5.3.1. Factor Xa Inhibitor
           5.3.2. Low Molecular Weight Heparin
           5.3.3. P2Y12 Platelet Inhibitor
           5.3.4. Others
    5.4. Market Attractiveness, by Drug Class

    Chapter 6. Global Thrombosis Drugs Market Analysis and Forecasts, by Indication
    6.1. Key Findings / Developments
    6.2. Introduction & Definition
    6.3. Market Value Forecast, by Indication, 2017–2026
           6.3.1. Pulmonary Embolism
           6.3.2. Atrial Fibrillation
           6.3.3. Deep Vein Thrombosis
           6.3.4. Others
    6.4. Market Attractiveness, by Indication

    Chapter 7. Global Thrombosis Drugs Market Analysis and Forecasts, by Distribution Channel
    7.1. Key Findings / Developments
    7.2. Introduction & Definition
    7.3. Market Value Forecast, by Distribution Channel, 2017–2026
           7.3.1. Hospital Pharmacies
           7.3.2. Retail Pharmacies
           7.3.3. Online Pharmacies
    7.4. Market Attractiveness, by Distribution Channel

    Chapter 8. Global Thrombosis Drugs Market Analysis and Forecasts, by Geography/Region
    8.1. Geographical Representation
    8.2. Market Value Forecast, by Region
           8.2.1. North America
           8.2.2. Europe
           8.2.3. Asia Pacific
           8.2.4. Latin America
           8.2.5. Middle East & Africa
    8.3. Market Attractiveness, by Region

    Chapter 9. North America Thrombosis Drugs Analysis and Forecast
    9.1. Market Value Forecast, by Country, 2017–2026
           9.1.1. U.S.
           9.1.2. Canada
    9.2. Market Value Share Analysis, by Drug Class, 2017–2026
    9.3. Market Value Forecast, by Drug Class, 2016–2026
           9.3.1. Factor Xa Inhibitor
           9.3.2. Low Molecular Weight Heparin
           9.3.3. P2Y12 Platelet Inhibitor
           9.3.4. Others
    9.4. Market Value Share Analysis, by Indication, 2017–2026
    9.5. Market Value Forecast, by Indication, 2016–2026
           9.5.1. Pulmonary Embolism
           9.5.2. Atrial Fibrillation
           9.5.3. Deep Vein Thrombosis
           9.5.4. Others
    9.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
    9.7. Market Value Forecast, by Distribution Channel, 2016–2026
           9.7.1. Hospital Pharmacies
           9.7.2. Retail Pharmacies
           9.7.3. Online Pharmacies
    9.8. Market Attractiveness Analysis
           9.8.1. By Country
           9.8.2. By Drug Class
           9.8.3. By Indication
           9.8.4. By Distribution Channel

    Chapter 10. Europe Thrombosis Drugs Market Analysis and Forecast
    10.1. Market Value Forecast, by Country , 2017–2025
           10.1.1. Germany
           10.1.2. France
           10.1.3. U.K.
           10.1.4. Spain
           10.1.5. Italy
           10.1.6. Rest of Europe
    10.2. Market Value Share Analysis, by Drug Class, 2017–2026
    10.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
           10.3.1. Factor Xa Inhibitor
           10.3.2. Low Molecular Weight Heparin
           10.3.3. P2Y12 Platelet Inhibitor
           10.3.4. Others
    10.4. Market Value Share Analysis, by Indication, 2017–2026
    10.5. Market Value Forecast, by Indication, 2016–2026
           10.5.1. Pulmonary Embolism
           10.5.2. Atrial Fibrillation
           10.5.3. Deep Vein Thrombosis
           10.5.4. Others
    10.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
    10.7. Market Value Forecast, by Distribution Channel, 2016–2026
           10.7.1. Hospital Pharmacies
           10.7.2. Retail Pharmacies
           10.7.3. Online Pharmacies
    10.8. Market Attractiveness Analysis
           10.8.1. By Country
           10.8.2. By Drug Class
           10.8.3. By Indication
           10.8.4. By Distribution Channel

    Chapter 11. Asia Pacific Thrombosis Drugs Market Analysis and Forecast
    11.1. Market Value Forecast, by Country , 2017–2025
           11.1.1. China
           11.1.2. Japan
           11.1.3. India
           11.1.4. Australia & New Zealand
           11.1.5. Rest of APAC
    11.2. Market Value Share Analysis, by Drug Class, 2017–2026
    11.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
           11.3.1. Factor Xa Inhibitor
           11.3.2. Low Molecular Weight Heparin
           11.3.3. P2Y12 Platelet Inhibitor
           11.3.4. Others
    11.4. Market Value Share Analysis, by Indication, 2017–2026
    11.5. Market Value Forecast, by Indication, 2016–2026
           11.5.1. Pulmonary Embolism
           11.5.2. Atrial Fibrillation
           11.5.3. Deep Vein Thrombosis
           11.5.4. Others
    11.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
    11.7. Market Value Forecast, by Distribution Channel, 2016–2026
           11.7.1. Hospital Pharmacies
           11.7.2. Retail Pharmacies
           11.7.3. Online Pharmacies
    11.8. Market Attractiveness Analysis
           11.8.1. By Country
           11.8.2. By Drug Class
           11.8.3. By Indication
           11.8.4. By Distribution Channel

    Chapter 12. Latin America Thrombosis Drugs Market Analysis and Forecast
    12.1. Market Value Forecast, by Country, 2017–2025
           12.1.1. Brazil
           12.1.2. Mexico
           12.1.3. Rest of LATAM
    12.2. Market Value Share Analysis, by Drug Class, 2017–2026
    12.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
           12.3.1. Factor Xa Inhibitor
           12.3.2. Low Molecular Weight Heparin
           12.3.3. P2Y12 Platelet Inhibitor
           12.3.4. Others
    12.4. Market Value Share Analysis, by Indication, 2017–2026
    12.5. Market Value Forecast, by Indication, 2016–2026
           12.5.1. Pulmonary Embolism
           12.5.2. Atrial Fibrillation
           12.5.3. Deep Vein Thrombosis
           12.5.4. Others
    12.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
    12.7. Market Value Forecast, by Distribution Channel, 2016–2026
           12.7.1. Hospital Pharmacies
           12.7.2. Retail Pharmacies
           12.7.3. Online Pharmacies
    12.8. Market Attractiveness Analysis
           12.8.1. By Country
           12.8.2. By Drug Class
           12.8.3. By Indication
           12.8.4. By Distribution Channel

    Chapter 13. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast
    13.1. Market Value Forecast, by Country, 2017–2025
           13.1.1. GCC Countries
           13.1.2. South Africa
           13.1.3. Israel
           13.1.4. Rest of Middle East & Africa
    13.2. Market Value Share Analysis, by Drug Class, 2017–2026
    13.3. Market Value and Volume Forecast, by Drug Class, 2016–2026
           13.3.1. Factor Xa Inhibitor
           13.3.2. Low Molecular Weight Heparin
           13.3.3. P2Y12 Platelet Inhibitor
           13.3.4. Others
    13.4. Market Value Share Analysis, by Indication, 2017–2026
    13.5. Market Value Forecast, by Indication, 2016–2026
           13.5.1. Pulmonary Embolism
           13.5.2. Atrial Fibrillation
           13.5.3. Deep Vein Thrombosis
           13.5.4. Others
    13.6. Market Value Share Analysis, by Distribution Channel, 2017–2026
    13.7. Market Value Forecast, by Distribution Channel, 2016–2026
           13.7.1. Hospital Pharmacies
           13.7.2. Retail Pharmacies
           13.7.3. Online Pharmacies
    13.8. Market Attractiveness Analysis
           13.8.1. By Country
           13.8.2. By Drug Class
           13.8.3. By Indication
           13.8.4. By Distribution Channel

    Chapter 14. Competition Landscape
    14.1. Competition Matrix
           14.1.1. GlaxoSmithKline plc. F. Hoffmann-La Roche Ltd.
           14.1.2. Baxter International, Inc.
    14.2. Company Profiles
           14.2.1. GlaxoSmithKline plc.
                    14.2.1.1. Company Details
                    14.2.1.2. Company Description
                    14.2.1.3. Business Overview
                    14.2.1.4. SWOT Analysis
                    14.2.1.5. Financial Analysis
                    14.2.1.6. Strategic Overview
           14.2.2. Baxter International, Inc.
                    14.2.2.1. Company Details
                    14.2.2.2. Company Description
                    14.2.2.3. Business Overview
                    14.2.2.4. SWOT Analysis
                    14.2.2.5. Strategic Overview
           14.2.3. Johnson & Johnson
                    14.2.3.1. Company Details
                    14.2.3.2. Company Description
                    14.2.3.3. Business Overview
                    14.2.3.4. SWOT Analysis
                    14.2.3.5. Strategic Overview
           14.2.4. Bayer AG
                    14.2.4.1. Company Details
                    14.2.4.2. Company Description
                    14.2.4.3. Business Overview
                    14.2.4.4. SWOT Analysis
                    14.2.4.5. Strategic Overview
           14.2.5. Sanofi
                    14.2.5.1. Company Details
                    14.2.5.2. Company Description
                    14.2.5.3. Business Overview
                    14.2.5.4. SWOT Analysis
                    14.2.5.5. Financial Analysis
                    14.2.5.6. Strategic Overview
           14.2.6. Bristol-Myers Squibb Company
                    14.2.6.1. Company Details
                    14.2.6.2. Company Description
                    14.2.6.3. Business Overview
                    14.2.6.4. SWOT Analysis
                    14.2.6.5. Financial Analysis
                    14.2.6.6. Strategic Overview
           14.2.7. AstraZeneca plc
                    14.2.7.1. Company Details
                    14.2.7.2. Company Description
                    14.2.7.3. Business Overview
                    14.2.7.4. SWOT Analysis
                    14.2.7.5. Financial Analysis
                    14.2.7.6. Strategic Overview
           14.2.8. Pfizer, Inc.
                    14.2.8.1. Company Details
                    14.2.8.2. Company Description
                    14.2.8.3. Business Overview
                    14.2.8.4. SWOT Analysis
                    14.2.8.5. Financial Analysis
                    14.2.8.6. Strategic Overview
           14.2.9. Boehringer Ingelheim GmbH
                    14.2.9.1. Company Details
                    14.2.9.2. Company Description
                    14.2.9.3. Business Overview
                    14.2.9.4. SWOT Analysis
                    14.2.9.5. Strategic Overview
           14.2.10. Aspen Pharmacare Holdings Limited
                    14.2.10.1. Company Details
                    14.2.10.2. Company Description
                    14.2.10.3. Business Overview
                    14.2.10.4. SWOT Analysis
                    14.2.10.5. Strategic Overview

    List of Tables

    Table 01: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 02: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 03: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 04: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Region, 2016–2026
    Table 05: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2026
    Table 06: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 07: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 08: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 09: U.S. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 10: U.S. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 11: U.S. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 12: Canada Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 13: Canada Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 14: Canada Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 15: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 16: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, Drug Class, 2016–2026
    Table 17: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 18: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 19: Germany Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 20: Germany Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 21: Germany Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 22: U.K. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 23: U.K. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 24: U.K. Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 25: France Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 26: France Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 27: France Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 28: Italy Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 29: Italy Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 30: Italy Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 31: Spain Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 32: Spain Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 33: Spain Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 34: Rest of Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 35: Rest of Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 36: Rest of Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 37: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 38: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 39: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 40: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 41: China Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 42: China Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 43: China Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 44: Japan Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 45: Japan Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 46: Japan Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 47: India Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 48: India Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 49: India Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 50: Australia & New Zealand Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 51: Australia & New Zealand Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 52: Australia & New Zealand Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 53: Rest of Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 54: Rest of Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 55: Rest of Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 56: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 57: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 58: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 59: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 60: Brazil Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 61: Brazil Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 62: Brazil Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 63: Mexico Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 64: Mexico Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 65: Mexico Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 66: Rest of Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 67: Rest of Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 68: Rest of Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 69: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 70: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 71: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 72: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 73: GCC Countries Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 74: GCC Countries Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 75: GCC Countries Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 76: South Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 77: South Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 78: South Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 79: Israel Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 80: Israel Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 81: Israel Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 82: Rest of Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 83: Rest of Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2016–2026
    Table 84: Rest of Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026

    List of Figures

    Figure 01: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, 2016–2026
    Figure 02: Global Thrombosis Drugs Y-o-Y Growth Rate (%), 2017–2026
    Figure 03: Market Value Share, by Drug Class (2017)
    Figure 04: Market Value Share, by Indication (2017)
    Figure 05: Market Value Share, by Distribution Channel (2017)
    Figure 07: Global Thrombosis Drugs Market, by Drug Product, 2017 and 2026
    Figure 08: Global Thrombosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Factor Xa Inhibitor, 2016–2026
    Figure 09: Global Thrombosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Low Molecular Weight Heparin, 2016–2026
    Figure 10: Global Thrombosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by P2Y12 Platelet Inhibitor, 2016–2026
    Figure 11: Global Thrombosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016–2026
    Figure 12: Global Thrombosis Drugs Market Attractiveness, by Drug Class, 2018–2025
    Figure 13: Global Thrombosis Drugs Market, by Indication, 2017 and 2026
    Figure 14: Global Thrombosis Drugs Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Indication: Pulmonary Embolism, 2016–2026
    Figure 15: Global Thrombosis Drugs Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Indication: Atrial Fibrillation, 2016–2026
    Figure 16: Global Thrombosis Drugs Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Indication: Deep Vein Thrombosis, 2016–2026
    Figure 17: Global Thrombosis Drugs Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Indication: Others, 2016–2026
    Figure 18: Global Thrombosis Drugs Market Attractiveness, by Indication, 2018–2025
    Figure 19: Global Thrombosis Drugs Market, by Distribution Channel, 2017 and 2026
    Figure 20: Global Thrombosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Hospital Pharmacies, 2016–2026
    Figure 21: Global Thrombosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Retail Pharmacies, 2016–2026
    Figure 22: Global Thrombosis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Online Pharmacies, 2016–2026
    Figure 23: Global Thrombosis Drugs Market Attractiveness, by Distribution Channel, 2018–2025
    Figure 24: Global Thrombosis Drugs Market Value Share, by Region, 2017 and 2026
    Figure 25: Thrombosis Drugs Market Attractiveness Analysis, by Region, 2017–2026
    Figure 26: North America Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 27: North America Thrombosis Drugs Market Value Share, by Country, 2017 and 2026
    Figure 28: North America Thrombosis Drugs Market Attractiveness, by Country, 2017–2026
    Figure 29: North America Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
    Figure 30: North America Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
    Figure 31: North America Thrombosis Drugs Market Value Share, by Indication, 2017 and 2026
    Figure 32: North America Thrombosis Drugs Market Attractiveness, by Indication, 2017–2026
    Figure 33: North America Thrombosis Drugs Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 34: North America Thrombosis Drugs Market Attractiveness, by Distribution Channel, 2017–2026
    Figure 35: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 36: Europe Thrombosis Drugs Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 37: Europe Thrombosis Drugs Market Attractiveness, by Country/Sub-region, 2017–2026
    Figure 38: Europe Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
    Figure 39: Europe Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
    Figure 40: Europe Thrombosis Drugs Market Value Share, Indication, 2017 and 2026
    Figure 41: Europe Thrombosis Drugs Market Attractiveness Analysis, Indication, 2017–2026
    Figure 42: Europe Thrombosis Drugs Market Value Share, Distribution Channel, 2017 and 2026
    Figure 43: Europe Thrombosis Drugs Market Attractiveness Analysis, Distribution Channel, 2017–2026
    Figure 44: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 45: Asia Pacific Thrombosis Drugs Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 46: Asia Pacific Thrombosis Drugs Market Attractiveness, by Country/Sub-region, 2017–2026
    Figure 47: Asia Pacific Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
    Figure 48: Asia Pacific Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
    Figure 49: Asia Pacific Thrombosis Drugs Market Value Share, Indication, 2017 and 2026
    Figure 50: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, Indication, 2017–2026
    Figure 51: Asia Pacific Thrombosis Drugs Market Value Share, Distribution Channel, 2017 and 2026
    Figure 52: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, Distribution Channel, 2017–2026
    Figure 53: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 54: Latin America Thrombosis Drugs Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 55: Latin America Thrombosis Drugs Market Attractiveness, by Country/Sub-region, 2017–2026
    Figure 56: Latin America Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
    Figure 57: Latin America Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
    Figure 58: Latin America Thrombosis Drugs Market Value Share, Indication, 2017 and 2026
    Figure 59: Latin America Thrombosis Drugs Market Attractiveness Analysis, Indication, 2017–2026
    Figure 60: Latin America Thrombosis Drugs Market Value Share, Distribution Channel, 2017 and 2026
    Figure 61: Latin America Thrombosis Drugs Market Attractiveness Analysis, Distribution Channel, 2017–2026
    Figure 62: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 63: Middle East & Africa Thrombosis Drugs Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 64: Middle East & Africa Thrombosis Drugs Market Attractiveness, by Country/Sub-region, 2017–2026
    Figure 65: Middle East & Africa Thrombosis Drugs Market Value Share, by Drug Class, 2017 and 2026
    Figure 66: Middle East & Africa Thrombosis Drugs Market Attractiveness, by Drug Class, 2017–2026
    Figure 67: Middle East & Africa Thrombosis Drugs Market Value Share, Indication, 2017 and 2026
    Figure 68: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, Indication, 2017–2026
    Figure 69: Middle East & Africa Thrombosis Drugs Market Value Share, Distribution Channel, 2017 and 2026
    Figure 70: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, Distribution Channel, 2017–2026

Copyright © Transparency Market Research, Inc. All Rights reserved